FDA Imposes Partial Clinical Hold on Biohaven's BHV-7000 Epilepsy Program
BHVN sits 80% above its 52-week low of $7.48.
Summary
Biohaven disclosed an FDA partial clinical hold on new enrollment in its BHV-7000 epilepsy program due to a nonclinical metabolite finding. Dosing continues for over 600 randomized patients, and the fully enrolled BHV7000-303 study remains on track for topline data in H2 2026.
Updates
· Dow Jones Newswires — The hold pauses enrollment in the RISE-2 study; RISE-3 data is expected later this year. William Blair's Myles Minter said the delay widens Xenon Pharmaceuticals' first-mover advantage.
· Reuters — Shares fell more than 13% premarket after the hold was disclosed. The pending SK Biopharmaceuticals licensing deal has not closed and is subject to antitrust review.
Key Events · Product Development and Regulatory · BHVN
-
FDA Partial Clinical Hold
On September 4, 2026, the FDA issued a partial clinical hold letter pausing new patient enrollment in the BHV-7000 program, pending additional nonclinical data on a specific metabolite observed in rodent testing.
-
Dosing Continues for 600+ Patients
The hold applies only to new enrollment; dosing continues for all patients already randomized across the program, more than 600 participants.
-
Pivotal Study Timeline Intact
BHV7000-303, one of two pivotal focal epilepsy studies, is fully enrolled and randomized; topline data remain on track for the second half of 2026.
-
Second Pivotal Study Enrollment Paused
BHV7000-302 will continue dosing but new enrollment is paused pending nonclinical data expected in the coming weeks; the open-label extension study also continues dosing.
Analysis · BHVN · Life Sciences
A nonclinical metabolite finding in rodent testing has prompted the FDA to pause new patient enrollment in Biohaven's lead BHV-7000 epilepsy program, raising questions about human safety. The hold is partial—dosing continues for more than 600 already-randomized patients, and the fully enrolled BHV7000-303 pivotal study remains on track for topline data in the second half of 2026. The key risk is that the additional nonclinical studies, expected in the coming weeks, could reveal a human-relevant safety issue that delays or derails the program. This matters because BHV-7000 is the centerpiece of the recently signed global licensing deal with SK Biopharmaceuticals, and any setback could affect that partnership's value.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 974 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BHVN was trading at $13.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $7.48 to $18.57. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.